The Surveillance of Hepatocellular Carcinoma

March 17, 2022 updated by: Ping Liang, Chinese PLA General Hospital

The Surveillance of Development and Progression of Hepatocellular Carcinoma

Early detection of hepatocellular carcinoma is vita to the prognosis of patient. In this study, the occurrence and development of liver cancer were supervised by imaging examination, and the dysplastic nodules will be distinguished from early hepatocellular carcinoma through macro-imaging and micro-pathological features.

Study Overview

Status

Recruiting

Conditions

Hepatocellular Carcinoma

Intervention / Treatment

Other: Imaging examination and/or blood test

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

China
- - Beijing, China
    - Recruiting
    - Chinese PLA General Hospital
    - Contact:
      
      Jie Yu
      
      Phone Number: 8601066939530
      
      Email: jiemi301@163.com
- Beijing
  - Beijing, Beijing, China, 100853
    - Recruiting
    - Chinese PLA General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with hepatitis B, liver cirrhosis, or atypical hyperplasia nodules confirmed or suspected by enhanced imaging examination will be enrolled, the contrast-enhanced ultrasound and/or enhanced magnetic resonance imaging will be performed every three months or half a year to observe the size and contrast-enhanced features of the nodules. If the size or enhancement features change, there will a puncture biopsy under the guidance of ultrasound, and if malignant tumor cells are found, the follow-up will be terminated.

Description

Inclusion Criteria:

- Patients with Hepatitis B and cirrhosis Accept regular imaging examination. Pathological diagnosis of liver cancer.

Exclusion Criteria:

- Can't tolerate the enhanced imaging examination Poor medical compliance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Cohort
Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effective detection of early hepatocellular carcinoma Time Frame: 2 years	The occurrence of early hepatocellular carcinoma	2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese PLA General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2022

Primary Completion (Anticipated)

July 1, 2023

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

February 22, 2022

First Submitted That Met QC Criteria

March 17, 2022

First Posted (Actual)

March 18, 2022

Study Record Updates

Last Update Posted (Actual)